诺诚健华(香港联交所代码:09969;上交所代码:688428)今天宣布,公司在2025年美国临床肿瘤学会(ASCO)年会上公布一系列创新管线最新数据,涉及抗 CCR8 抗体ICP-B05(CM369)、BCL2 抑制剂 mesutoclax(ICP-248)和泛TRK抑制剂zurletrectinib (ICP-723)。口头报告标题:抗CCR8抗体治疗复发/难治性皮肤 T 细胞淋巴瘤(CTCL...
Source Link诺诚健华(香港联交所代码:09969;上交所代码:688428)今天宣布,公司在2025年美国临床肿瘤学会(ASCO)年会上公布一系列创新管线最新数据,涉及抗 CCR8 抗体ICP-B05(CM369)、BCL2 抑制剂 mesutoclax(ICP-248)和泛TRK抑制剂zurletrectinib (ICP-723)。口头报告标题:抗CCR8抗体治疗复发/难治性皮肤 T 细胞淋巴瘤(CTCL...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.